Mortality in psoriatic arthritis patients, changes over time, and the impact of COVID-19: results from a multicenter Psoriatic Arthritis Registry (PsART-ID).
Abdulsamet ErdenGizem AyanLevent KilicDilek SolmazSibel BakirciGezmis KimyonEsen Kasapoglu GünalAtalay DogruOzun BayindirEdiz DalkilicCem ÖzislerServet AkarGözde Yildirim CetinEmine Figen TarhanOrhan KüçüksahinAhmet OmmaEmel GonulluFatih YildizEmine Duygu ErsozluMuhammed CinarAbdurrahman TufanSeval PehlevanSerpil Ergulu EsmenSema YilmazTuncay DuruozTimucin KasifogluVeli YazısızKenan AksuSibel Zehra AydinUmut KalyoncuPublished in: Clinical rheumatology (2023)
The mortality in PsA was found similar to the general population in the pre-pandemic era. The mortality rates in PsA doubled during the pandemic. Whether PsA patients have more risk of mortality than the general population due to COVID-19 needs further studies. Key Points • Decrease in mortality in PsA might be expected with the more effective treatment options and better disease control. • A crude mortality rate is comparable to the general population and not increased until the pandemic. • Currently, there is a 2-fold increase in crude mortality rate possibly due to the COVID-19.